vs
Side-by-side financial comparison of ETHAN ALLEN INTERIORS INC (ETD) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $135.8M, roughly 1.3× ETHAN ALLEN INTERIORS INC). ETHAN ALLEN INTERIORS INC runs the higher net margin — 4.4% vs 1.6%, a 2.7% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -4.8%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -10.2%).
Ethan Allen Interiors Inc. is an American manufacturer and retailer of home furnishings, incorporated in Delaware with executive offices in Danbury, Connecticut. As of June 30, 2023, the company reported net annual sales of $791.4 million.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ETD vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $135.8M | $177.4M |
| Net Profit | $5.9M | $2.9M |
| Gross Margin | 59.4% | — |
| Operating Margin | 4.8% | 3.9% |
| Net Margin | 4.4% | 1.6% |
| Revenue YoY | -4.8% | 5.0% |
| Net Profit YoY | -38.2% | — |
| EPS (diluted) | $0.23 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $135.8M | $177.4M | ||
| Q4 25 | $149.9M | $196.9M | ||
| Q3 25 | $147.0M | $179.5M | ||
| Q2 25 | $160.4M | $181.1M | ||
| Q1 25 | $142.7M | $168.9M | ||
| Q4 24 | $157.3M | $187.3M | ||
| Q3 24 | $154.3M | $168.6M | ||
| Q2 24 | $168.6M | $178.0M |
| Q1 26 | $5.9M | $2.9M | ||
| Q4 25 | $11.7M | — | ||
| Q3 25 | $10.5M | $5.4M | ||
| Q2 25 | — | $-4.8M | ||
| Q1 25 | $9.6M | $4.8M | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $14.7M | $-143.5M | ||
| Q2 24 | $18.5M | $18.9M |
| Q1 26 | 59.4% | — | ||
| Q4 25 | 60.9% | 79.5% | ||
| Q3 25 | 61.4% | 80.9% | ||
| Q2 25 | 59.9% | 77.4% | ||
| Q1 25 | 61.2% | 79.7% | ||
| Q4 24 | 60.3% | 78.7% | ||
| Q3 24 | 60.8% | 76.9% | ||
| Q2 24 | 60.8% | 75.1% |
| Q1 26 | 4.8% | 3.9% | ||
| Q4 25 | 9.5% | 1.2% | ||
| Q3 25 | 6.8% | 3.5% | ||
| Q2 25 | 9.5% | 4.7% | ||
| Q1 25 | 7.7% | 1.2% | ||
| Q4 24 | 11.5% | 13.2% | ||
| Q3 24 | 11.4% | -82.8% | ||
| Q2 24 | 13.4% | 15.9% |
| Q1 26 | 4.4% | 1.6% | ||
| Q4 25 | 7.8% | — | ||
| Q3 25 | 7.1% | 3.0% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | 6.7% | 2.8% | ||
| Q4 24 | 9.5% | — | ||
| Q3 24 | 9.5% | -85.1% | ||
| Q2 24 | 11.0% | 10.6% |
| Q1 26 | $0.23 | $0.07 | ||
| Q4 25 | $0.46 | $0.05 | ||
| Q3 25 | $0.41 | $0.12 | ||
| Q2 25 | $0.48 | $-0.11 | ||
| Q1 25 | $0.37 | $0.10 | ||
| Q4 24 | $0.59 | $0.38 | ||
| Q3 24 | $0.57 | $-3.11 | ||
| Q2 24 | $0.73 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.6M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $473.7M | $653.9M |
| Total Assets | $723.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $66.6M | $144.3M | ||
| Q4 25 | $139.3M | $238.4M | ||
| Q3 25 | $123.6M | $246.3M | ||
| Q2 25 | $136.1M | $445.9M | ||
| Q1 25 | $172.9M | $493.6M | ||
| Q4 24 | $139.1M | $484.6M | ||
| Q3 24 | $135.9M | $453.8M | ||
| Q2 24 | $161.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $473.7M | $653.9M | ||
| Q4 25 | $478.2M | $693.1M | ||
| Q3 25 | $475.5M | $727.2M | ||
| Q2 25 | $482.4M | $757.8M | ||
| Q1 25 | $479.2M | $798.5M | ||
| Q4 24 | $478.8M | $778.3M | ||
| Q3 24 | $474.7M | $749.6M | ||
| Q2 24 | $483.0M | $879.3M |
| Q1 26 | $723.3M | $1.2B | ||
| Q4 25 | $714.8M | $1.3B | ||
| Q3 25 | $737.1M | $1.3B | ||
| Q2 25 | $737.1M | $1.5B | ||
| Q1 25 | $738.7M | $1.6B | ||
| Q4 24 | $732.6M | $1.6B | ||
| Q3 24 | $737.7M | $1.5B | ||
| Q2 24 | $744.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ETD
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
